reports
Informations relatives au nombre total de droits de vote et d’actions ...
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 6 mars 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), société intégrée de biotechnologie qui développe des immunothérapies innovantes, en direct ou via des partenariats, pour l’activation et la régulation immunitaire en immuno-oncologie et en immuno-inflammation, informe ses actionnaires du nombre total de droits de vote et d’actions composant son capital à ...
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 03 March 2026) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in March. TD Cowen 46th Annual Healthcare Conference Presentation: Tuesday, March 3, 2026, at 2:30 p.m. E...
- Delphine Brault
- Juan Ros-Padilla
- Luis de Toledo Heras
- Nathan Mietlicki
EDP EDP-ENERGIAS DE PORTUGAL SA
MT ARCELORMITTAL SA
BVI BUREAU VERITAS SA
BEKB BEKAERT SA
SU SCHNEIDER ELECTRIC SE
KNEBV KONE OYJ CLASS B
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
OSE OSE IMMUNOTHERAPEUTICS SA
SSAB A SSAB AB CLASS A
ABB ABB LTD.
SAND SANDVIK AB
RXL REXEL SA
SZG SALZGITTER AG
ITRK INTERTEK GROUP PLC
VOE VOESTALPINE AG
ACX ACERINOX SA
ALO ALSTOM SA
SCHP SCHINDLER HOLDING AG PREF
ERA ERAMET SA
REP REPSOL SA
NDA AURUBIS AG
DOKA DORMAKABA HOLDING AG
MOCORP METSO OUTOTEC OYJ
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
CPINV CARE PROPERTY INVEST SA
ITX INDUSTRIA DE DISENO TEXTIL S.A.
ASSA B ASSA ABLOY AB CLASS B
NVG NAVIGATOR COMPANY SA
RIO RIO TINTO PLC
SIE SIEMENS AG
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
VOS VOSSLOH AG
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
S92 SMA SOLAR TECHNOLOGY AG
KBX KNORR-BREMSE AG
THEP THERMADOR HOLDING SA
SRAIL STADLER RAIL AG
ENR SIEMENS ENERGY AG
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
VUL VULCAN ENERGY RESOURCES
AG1 AUTO1 GROUP
OVH OVH GROUPE
EPI A EPIROC AB
ALLFG ALLFUNDS (UK) LTD
ATCO A ATLAS COPCO AB
SGSN SGS SA
AAL ANGLO AMERICAN PLC
AENA AENA S.M.E. SA
SHA SCHAEFFLER AG
CIRSA CIRSA ENTERPRISES S.A.
- Delphine Brault
- Emira Sagaama
- Juan Ros-Padilla
- Luis de Toledo Heras
- Nathan Mietlicki
EDP EDP-ENERGIAS DE PORTUGAL SA
MT ARCELORMITTAL SA
BVI BUREAU VERITAS SA
BEKB BEKAERT SA
SU SCHNEIDER ELECTRIC SE
KNEBV KONE OYJ CLASS B
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
OSE OSE IMMUNOTHERAPEUTICS SA
SSAB A SSAB AB CLASS A
ABB ABB LTD.
SAND SANDVIK AB
RXL REXEL SA
SZG SALZGITTER AG
ITRK INTERTEK GROUP PLC
VOE VOESTALPINE AG
ACX ACERINOX SA
ALO ALSTOM SA
SCHP SCHINDLER HOLDING AG PREF
ERA ERAMET SA
REP REPSOL SA
NDA AURUBIS AG
DOKA DORMAKABA HOLDING AG
MOCORP METSO OUTOTEC OYJ
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
CPINV CARE PROPERTY INVEST SA
ITX INDUSTRIA DE DISENO TEXTIL S.A.
ASSA B ASSA ABLOY AB CLASS B
NVG NAVIGATOR COMPANY SA
RIO RIO TINTO PLC
SIE SIEMENS AG
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
VOS VOSSLOH AG
CAF CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
S92 SMA SOLAR TECHNOLOGY AG
KBX KNORR-BREMSE AG
THEP THERMADOR HOLDING SA
SRAIL STADLER RAIL AG
ENR SIEMENS ENERGY AG
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
VUL VULCAN ENERGY RESOURCES
AG1 AUTO1 GROUP
OVH OVH GROUPE
EPI A EPIROC AB
ALLFG ALLFUNDS (UK) LTD
ATCO A ATLAS COPCO AB
SGSN SGS SA
AAL ANGLO AMERICAN PLC
AENA AENA S.M.E. SA
CIRSA CIRSA ENTERPRISES S.A.
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Martial Descoutures
- Martial Descoutures
OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Lat...
OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi® Streamlining of selected non‑strategic early-stage programs completed, consistent with previously announced three-year 2026-2028 strategic planNo impact on cash runway or financing strategy as no milestone associated with these programs was expected within this three-year timeframeFocused investment on high‑value late‑stage assets Lusvertikimab and Tedopi® Multiple clinical catalysts expected from 2026 to 2028 Nantes, France, March 2, 2026 – 6:00pm CET - OSE Immunotherapeut...
OSE Immunotherapeutics accélère son recentrage stratégique autour de s...
OSE Immunotherapeutics accélère son recentrage stratégique autour de ses principaux leviers de création de valeur en phase avancée: Lusvertikimab et Tedopi® Dépriorisation de certains programmes précoces non stratégiques, conformément au plan stratégique à 3 ans 2026–2028 précédemment annoncéAucun impact sur la visibilité financière ni sur la stratégie de financement, aucun jalon associé à ces programmes n’étant attendu sur cette période de trois ansInvestissements concentrés sur les actifs à forte valeur et à un stade avancé de développement : lusvertikimab et Tedopi®Multiples jalons clini...
OSE Immunotherapeutics reçoit un deuxième avis positif du Comité Indép...
OSE Immunotherapeutics reçoit un deuxième avis positif du Comité Indépendant de Surveillance des Données (IDMC) pour l’essai pivot de Phase 3 ARTEMIA évaluant Tedopi® dans le cancer du poumon non à petites cellules Nantes, le 26 février 2026 – 18h00 CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo : OSE) annonce aujourd’hui que le Comité Indépendant de Surveillance des Données (IDMC) a émis une deuxième recommandation positive concernant l’essai pivot de Phase 3 ARTEMIA en cours, évaluant Tedopi® dans le cancer du poumon non à petites cellules (CPNPC) à un stade avancé. L’IDMC a r...
OSE Immunotherapeutics Receives Second Positive IDMC Recommendation fo...
OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer NANTES, France, February 26, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced that the Independent Data Monitoring Committee (IDMC) has issued a second positive recommendation for the ongoing pivotal Phase 3 ARTEMIA trial evaluating Tedopi® in advanced non-small cell lung cancer (NSCLC). The IDMC advised that the study should continue as planned, with no protocol changes. In line with the predefined study ...
Immunocore reports fourth quarter and full year 2025 financial results...
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; expect moderating revenue growth in 2026 TEBE-AM enrollment completion anticipated 1H 2026 with topline data expected as early as 2H 2026 PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp in ovarian and lung cancer, and initial data with half-life extended candidate (IM...
BioNTech veröffentlicht am 10. März 2026 Ergebnisse für das vierte Qua...
BioNTech veröffentlicht am 10. März 2026 Ergebnisse für das vierte Quartal und das Geschäftsjahr 2025 und informiert über operativen Fortschritt MAINZ, Deutschland, 24. Februar 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Dienstag, den 10. März 2026, die Ergebnisse für das vierte Quartal und das Geschäftsjahr 2025 veröffentlichen. Darüber hinaus wird das Unternehmen am selben Tag um 13:00 Uhr MEZ (8:00 Uhr Eastern Standard Time) eine Telefonkonferenz samt Webcast für Investoren, Finanzanalysten sowie die allgemeine Öffentlichkeit durchführen, um die Fi...
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results...
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026 MAINZ, Germany, February 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the fourth quarter and full year 2025 on Tuesday, March 10, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, pl...
Immunocore to report fourth quarter and full year 2025 financial resul...
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 18 February 2026) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year e...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarte...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. “As we close out the fourth quarter, CRISPR Therapeutics continues to make steady progress across a broad and increasingly mature pipeline,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “We made meaningful advances across multiple clinical and pr...
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
QLYS QUALYS INC.
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
CYBR CYBERARK SOFTWARE LTD.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
NFLX NETFLIX INC.
HNSA HANSA BIOPHARMA AB
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
TSEM TOWER SEMICONDUCTOR LTD
DT DYNATRACE INC.
SMCI SUPER MICRO COMPUTER
BEAM INC.
U BEAM THERAPEUTICS
DAWN UNITY SOFTWARE
FNMA DAY ONE BIOPHARMACEUTICALS INC
STX FEDERAL NATIONAL MORTGAGE ASSOCIATION
APP SEAGATE TECHNOLOGY HLDGS PLC
GFS APPLOVIN CORP
GLOBALFOUNDRIES INC
- David Nierengarten
- Dennis Pak
- Martin Fan
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
Transgene Announces Financial Calendar for 2026
Transgene Announces Financial Calendar for 2026 Strasbourg, France, February 4, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG) a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its financial reporting and Annual shareholders’ meeting dates for 2026: March 24, 2026: 2025 Fiscal Year Results April 29, 2026: First Quarter 2026 Financial Results May 13, 2026: Annual Shareholders’ Meeting September 24, 2026: First Half 2026 Financial Results November 9, 2026: ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.